EX-99.1 2 exh_991.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

 

 

 

 

 

 

 

 

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

As at and for the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

 

 

 

 

 

 

 

 

XORTX THERAPEUTICS INC.

Condensed Interim Consolidated Statements of Financial Position

(Unaudited - expressed in U.S. Dollars)

 

   Note 

September 30,

2023

  

December 31,

2022

Restated

(Note 2)

  

January 1,

2022

Restated

(Note 2)

 
       $    $    $ 
Assets                  
                   
Current                  
Cash  5   5,069,233    10,434,196    14,869,861 
Accounts receivable      68,241    81,752    40,654 
Prepaid expenses  6   88,927    379,620    1,002,215 
                   
Total Current Assets      5,226,401    10,895,568    15,912,730 
Non-current                  
Contract payments  7   1,200,000    1,185,946    1,267,065 
Intangible assets  8   171,521    199,834    202,125 
Property and equipment  9   42,225    92,678    - 
                   
Total Assets      6,640,147    12,374,026    17,381,920 
                   
Liabilities                  
                   
Current                  
Accounts payable and accrued liabilities  10,13   525,245    1,445,213    552,948 
Current portion of lease obligation  11   28,512    66,090    - 
                   
Total Current Liabilities      553,757    1,511,303    552,948 
Non-current                  
Derivative warrant liability  12(g)   -    3,854,403    3,626,375 
Lease obligation  11   -    11,509    - 
                   
Total Liabilities      553,757    5,377,215    4,179,323 
                   
Shareholders’ Equity                  
                   
Share capital  12   17,056,535    16,524,354    16,088,677 
Share-based payments, warrant reserve and other  12   9,611,845    6,197,158    4,991,594 
Obligation to issue shares  8(c)   24,746    24,746    24,746 
Accumulated other comprehensive (loss) income      (52,605)   (52,605)   75,540 
Accumulated deficit      (20,554,131)   (15,696,842)   (7,977,960)
                   
Total Shareholders’ Equity      6,086,390    6,996,811    13,202,597 
                   
Total Liabilities and Shareholders’ Equity      6,640,147    12,374,026    17,381,920 

 

 

 

/s/ “Allen Davidoff”   /s/ “Paul Van Damme”
Director   Director

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

 2 

 

XORTX THERAPEUTICS INC.

Condensed Interim Consolidated Statements of Comprehensive Loss

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

     

Three months ended

September 30

  

Nine months ended

September 30

 
  

 

 

Note

  2023  

2022

Restated

(Note 2)

   2023  

2022

Restated

(Note 2)

 
       $    $    $    $ 
Expenses                       
                        
Research and development  13   569,713    1,472,856    2,284,583    4,858,614 
Wages and benefits  13   118,566    132,559    419,900    444,176 
Consulting  13   130,467    111,563    357,051    222,101 
Directors’ fees  13   46,469    45,495    133,911    80,495 
Investor relations      236,934    100,706    640,556    746,232 
Professional fees  13   102,617    56,244    457,900    361,637 
General and administrative      90,140    117,236    281,938    360,598 
Public company costs      45,822    25,105    140,554    89,533 
Travel      14,267    84    138,416    11,497 
Amortization of property and equipment  8   18,329    18,308    54,763    24,264 
Amortization of intangible assets  9   (1,862)   3,749    60,571    11,325 
Share-based payments  12(f),13   21,850    19,268    92,169    420,258 
                        
Loss before other items      (1,393,312)   (2,103,173)   (5,062,312)   (7,630,730)
                        
Fair value adjustment on derivative warrant liability  12(g)   -    362,688    -    1,816,335 
Foreign exchange (loss)/gain      (3,668)   507,859    1,295    624,823 
Interest income      63,614    35,460    203,728    49,873 
                        
Net loss for the period      (1,333,366)   (1,197,166)   (4,857,289)   (5,139,699)
                        
Other comprehensive loss:                       
Items that may be subsequently reclassified to profit or loss:                       
Currency translation differences      -    (511,862)   -    (671,495)
Total other comprehensive loss for the period      -    (511,862)   -    (671,495)
                        
Total comprehensive loss for the period      (1,333,366)   (1,709,028)   (4,857,289)   (5,811,194)
                        
Basic and diluted loss per common share      (0.67)   (0.83)   (2.45)   (3.56)
                        
Weighted average number of common shares outstanding                       

Basic and diluted

      1,998,848    1,443,293    1,975,972    1,443,293 

 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

 3 

 

XORTX THERAPEUTICS INC.

Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity

(Unaudited - expressed in U.S. Dollars)

 

   Note  Number of
common
shares
  

Share

capital

   Reserves   Obligation
to issue
shares
   Accumulated
Deficit
   Accumulated
other
comprehensive
(loss) income
   Total 
            $    $    $    $    $    $ 
                                       
                                       

Balance, December 31, 2021

(Restated Note 2)

      1,443,293    16,088,677    4,991,594    24,746    (7,977,960)   75,540    13,202,597 
                                       
Share-based payments  12(f)   -    -    420,258    -    -    -    420,258 
Comprehensive loss for the period      -    -    -    -    (5,139,699)   (671,495)   (5,811,194)
                                       

Balance, September 30, 2022

(Restated Note 2)

      1,443,293    16,088,677    5,411,852    24,746    (13,117,659)   (595,955)   7,811,661 
                                       
Shares issued pursuant to public offering  12(b)   155,555    359,868    -    -    -    -    359,868 
Pre-funded warrants issued  12(b)   -    -    925,015    -    -         925,015 
Share issuance costs  12(b)   -    (88,959)   (42,687)   -    -    -    (131,646)
Pre-funded warrants exercised  12(b)   71,223    164,768    (164,704)   -    -    -    64 
Share-based payments  12(f)   -    -    67,682    -    -    -    67,682 
Comprehensive income (loss) for the period      -    -    -    -    (2,579,183)   543,350    (2,035,833)
                                       

Balance, December 31, 2022

(Restated Note 2)

      1,670,071    16,524,354    6,197,158    24,746    (15,696,842)   (52,605)   6,996,811 
                                       
Reclassification of derivative warrant liability  12(g)   -    -    3,854,403    -    -    -    3,854,403 
Pre-funded warrants exercised  12(b)   328,777    532,181    (531,885)   -    -    -    296 
Share-based payments  12(f)   -    -    92,169    -    -    -    92,169 
Comprehensive loss for the period      -    -    -    -    (4,857,289)   -    (4,857,289)
                                       
Balance, September 30, 2023      1,998,848    17,056,535    9,611,845    24,746    (20,554,131)   (52,605)   6,086,390 

 

The shares outstanding presented have been adjusted to reflect the effect of the 9:1 share consolidation that took place on November 10, 2023. Common shares, options, warrants and per share amounts have been adjusted for the 9:1 share consolidation unless otherwise noted.

 

 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

 4 

 

XORTX THERAPEUTICS INC.

Condensed Interim Consolidated Statements of Cash Flows

For the nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

   Nine months ended September 30 
   2023  

2022

Restated (Note 2)

 
    $    $ 
           
Cash provided by (used in):           
           
Operating activities          
Net loss for the period   (4,857,289)   (5,139,699)
           
Items not affecting cash:          
Amortization   115,334    35,589 
Fair value adjustment on derivative warrant liability   -    (1,816,335)
Share-based payments   92,169    420,258 
Unrealized foreign exchange gain   (16,778)   (565,198)
Changes in non-cash operating assets and liabilities:          
Accounts receivable   13,511    (22,490)
Prepaid expenses   290,693    937,057 
Accounts payable and accrued liabilities   (922,738)   801,038 
    (5,285,098)   (5,349,780)
           
Investing activities          
Acquisition of intangible assets   (32,258)   (14,614)
Acquisition of equipment   (4,310)   (14,272)
    (36,568)   (28,886)
           
Financing activities          
Pre-funded warrants and warrants exercised   296    - 
Payment of lease obligation   (49,087)   (18,423)
Deferred share issuance costs   -    (448,554)
    (48,791)   (466,977)
           
Effect of foreign exchange gain (loss) on cash   5,494    (152,248)
           
Decrease in cash   (5,364,963)   (5,997,891)
           
Cash, beginning of period   10,434,196    14,869,861 
           
Cash, end of period   5,069,233    8,871,970 
           
Supplemental Cash Flow and Non-Cash Investing Activities Disclosure          
Recognition of right-of-use asset    -    114,588 

 

 5 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

1.Nature of operations

 

XORTX Therapeutics Inc. (the “Company” or “XORTX”) was incorporated under the laws of Alberta, Canada on August 24, 2012.

 

XORTX is a public company listed on the TSX Venture Exchange (the “TSXV”) and on the Nasdaq Stock Market (“Nasdaq”) under the symbol “XRTX”. The Company’s operations and mailing address is 3710 – 33rd Street NW, Calgary, Alberta, Canada T2L 2M1 and its registered address is located at 550 Burrard Street, Suite 2900, Vancouver, British Columbia, V6C 0A3.

 

XORTX is a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy, and fatty liver disease. The Company’s current focus is on developing products to slow and/or reverse the progression of kidney disease in patients at risk of end stage kidney failure.

 

The Company is subject to a number of risks associated with the successful development of new products and their marketing and the conduct of its clinical studies and their results. The Company will have to finance its research and development activities and its clinical studies. To achieve the objectives in its business plan, the Company plans to raise the necessary capital and to generate revenues. Although there is no certainty, management is of the opinion that additional funding for future projects and operations can be raised as needed. The products developed by the Company will require approval from the U.S. Food and Drug Administration and equivalent organizations in other countries before their sale can be authorized. If the Company is unsuccessful in obtaining adequate financing in the future, research activities will be postponed until market conditions improve.

 

2.Basis of preparation

 

Statement of Compliance

 

These condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34 (IAS 34), Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”) and interpretations of the IFRS Interpretations Committee (“IFRIC”). Accordingly, certain disclosures included in the annual financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) have been condensed or omitted. These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2022.

 

Basis of Measurement and Presentation

 

These condensed interim consolidated financial statements have been prepared using the historical cost convention except for financial instruments which have been measured at fair value as explained in the notes to these condensed interim consolidated financial statements. These condensed interim consolidated financial statements were prepared on an accrual basis except for cash flow information.

 

 

 

 

 

 6 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

2.Basis of preparation (continued)

 

Basis of Measurement and Presentation (continued)

 

In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. The accounting policies have been applied consistently to all periods presented in these condensed interim consolidated financial statements.

 

These condensed interim consolidated financial statements incorporate the financial statements of the Company and its 100% owned subsidiary, XORTX Pharma Corp. The accounts of the Company’s subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated.

 

These condensed interim consolidated financial statements were approved for issue by the Board of Directors on November 14, 2023.

 

Change in functional and presentation currency

 

Determination of functional currency may involve certain judgments to determine the primary economic environment, and management reconsiders the functional currency of the Company and its subsidiary if there is a change in events and conditions which determine the primary economic environment. The Company had determined that the functional currency of the Company’s Canadian operations has changed from Canadian dollars (“CAD”) to United States dollars (“USD”) as the primary economic environment for the Company changed due to changing sources of recent and expected future sources of financing. The change in functional currency from CAD to USD is accounted for prospectively from January 1, 2023.

 

Concurrent with the change in functional currency, the Company has also changed its presentation currency from CAD to USD. This change in presentation currency is to better reflect the Company’s business activities, following the increased presence in the U.S. and to be consistent with peer companies in the industry. Under IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors, the change in presentation currency represents a voluntary change in accounting policy and is applied retrospectively. The comparative consolidated statements of comprehensive loss and consolidated statements of cash flows for each period have been translated into the presentation currency using the average exchange rate prevailing during each period. All assets, liabilities and equity transactions have been translated using the exchange rate prevailing on the consolidated statements of financial position dates.

 

Prior period comparable information has been restated to reflect the change in presentation currency. All revenues and expenses were translated into USD at the average exchange rate for each quarter, with no adjustments to the measurement of or accounting for previously reported results. The exchange rates used to reflect the change in presentation currency were as follows:

 

CAD – USD exchange rate Q1-22 Q2-22 Q3-22 Q4-22 Q4-21
Closing rate 0.8003 0.7760 0.7296 0.7383 0.7888
Average rate 0.7898 0.7834 0.7662 0.7366 0.7936

 

Foreign currency transactions are translated into the functional currency using exchange rates in effect at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate in effect at the measurement date. Non-monetary assets and liabilities denominated in foreign currencies are translated using the historical exchange rate or the exchange rate in effect at the measurement date for items recognized at fair value through profit and loss. Gains and losses arising from foreign exchange are included in profit and loss.

 

 7 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

2.Basis of preparation (continued)

 

Change in functional and presentation currency (continued)

 

Consolidated Statements of Financial Position

    December 31, 2022   January 1, 2022
    As reported,
CAD
  Restated,
USD
  As reported,
CAD
  Restated,
USD
Total current assets $ 14,750,412 $ 10,895,568 $ 20,173,339 $ 15,912,730
Total assets $ 16,752,929 $ 12,374,026 $ 22,035,902 $ 17,381,920
Total current liabilities $ 2,050,262 $ 1,511,303 $ 700,999 $ 552,948
Total liabilities $ 7,286,499 $ 5,377,215 $ 5,298,331 $ 4,179,323
Total shareholders’ equity $ 9,466,430 $ 6,996,811 $ 16,737,571 $ 13,202,597

 

Condensed Interim Consolidated Statements of Comprehensive Loss

    Three months ended
September 30, 2022
  Nine months ended
September 30, 2022
    As reported,
CAD
  Restated,
USD
  As reported,
CAD
  Restated,
USD
Loss before other items $ (2,744,942) $ (2,103,173) $ (9,771,049) $ (7,630,730)
Net loss $ (1,562,474) $ (1,197,166) $ (6,567,100) $ (5,139,699)
Net loss and comprehensive Loss $ (1,562,474) $ (1,709,028) $ (6,567,100) $ (5,811,194)
Basic and diluted loss per common share $ (1.08) $ (0.83) $ (4.55) $ (3.56)

 

Condensed Interim Consolidated Statements of Cash Flows

    Nine months ended
September 30, 2022
 
    As reported, CAD   Restated, USD  
Cash used in operating activities

$

(6,811,510) $ (5,349,780)  
Cash used in investing activities

$

(38,336) $ (28,886)  
Cash used in financing activities

$

(643,567) $ (466,977)  
Effect of foreign exchange on cash

$

802,216 $ (152,248)  
Net decrease in cash $ (6,691,197) $ (5,997,891)  
Cash beginning of period $ 18,851,244 $ 14,869,861  
Cash end of period $ 12,160,047 $ 8,871,970  

 

3.Accounting policies

 

These condensed interim consolidated financial statements have been prepared on a basis consistent with the significant accounting policies disclosed in the annual financial statements for the year ended December 31, 2022. Accordingly, they should be read in conjunction with the annual consolidated financial statements for the year ended December 31, 2022.

 

 8 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

4.Critical accounting judgments and estimates

 

The preparation of condensed interim consolidated financial statements requires management to make judgments and estimates that affect the amounts reported in the condensed interim consolidated financial statements and notes. By their nature, these judgments and estimates are subject to change and the effect on the condensed interim consolidated financial statements of changes in such judgments and estimates in future periods could be material. These judgments and estimates are based on historical experience, current and future economic conditions, and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual results could differ from these judgments and estimates.

 

Revisions to accounting estimates are recognized in the period in which the estimate is revised and may affect both the period of revision and future periods. Information about critical accounting judgments in applying accounting policies that have the most significant risk of causing material adjustment to the carrying amounts of assets and liabilities recognized in the condensed interim consolidated financial statements within the next financial year are discussed below:

 

Share-based payment transactions

The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the share option, volatility and dividend yield and making assumptions about them.

 

Classification of contract payments

In concluding that contract payments are a non-current asset, management considered when future regulatory and clinical trial programs are anticipated to be completed. Management assessed that the future regulatory and clinical trial programs would not be completed within 12 months from period end and therefore reclassified contract payments as a non-current asset.

 

Impairment of intangible assets

Patents (obtained and pending) and licenses are reviewed for impairment at each financial reporting date. If, in the judgment of management, future economic benefits will not flow to the Company, then the Company will assess the recoverable value of the asset. If the carrying value is greater than the recoverable value, the asset will be impaired to the recoverable value.

 

Determination of functional currency

In concluding that the U.S. dollar is the functional currency of the Company and its subsidiary, management considered the currency that mainly influences the cost of providing goods and services in the primary economic environment in which each entity operates, or if there has been a change in events or conditions that determined the primary economic environment.

 

Treatment of research and development costs

Costs to develop products are capitalized to the extent that the criteria for recognition as intangible assets in IAS 38 Intangible Assets are met. Those criteria require that the product is technically and economically feasible, the Company has the intention and ability to use the asset, and how the asset will generate future benefits. Management assessed the capitalization of development costs based on the attributes of the development project, perceived user needs, industry trends and expected future economic conditions. Management considers these factors in aggregate and applies significant judgment to determine whether the product is feasible. The Company has not capitalized any development costs as at September 30, 2023.

 

 

 

 9 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

4.Critical accounting judgments and estimates (continued)

 

Leases

Value of right-of-use assets and lease obligations require judgement in determining lease terms such as extension options, determining whether a lease contract contains an identified asset to which the Company has the right to use substantially all of the economic benefits from the use of that asset and the incremental borrowing rate applied. The Company estimates the incremental borrowing rate based on the lease term, collateral assumptions and the economic environment in which the lease is denominated. Renewal options are only included if management is reasonably certain that the option will be renewed.

 

Classification of pre-funded warrants

Management applied judgment when determining the appropriate classification of pre-funded warrants included in unit offerings. Management considered the characteristics of derivative instruments and concluded that the pre-funded warrants should be classified as an equity instrument.

 

5.Cash

 

The Company’s cash equivalents consist of cash held and interest-bearing deposits with the Company’s bank and brokerage accounts. The current annual interest rate earned on these deposits is 5.15% (December 31, 2022 - 3.90%).

 

  

September 30,

2023

  

December 31,

2022

  

January 1,

2022

 
    $    $    $ 
                
Cash   344,229    3,823,217    14,869,861 
Interest-bearing deposits   4,725,004    6,610,979    - 
    5,069,233    10,434,196    14,869,861 

 

6.Prepaid expenses

 

The Company’s prepaid expenses relate to the following:

 

  

September 30,

2023

  

December 31

2022

  

January 1,

2022

 
    $    $    $ 
                
Research and development   -    -    563,768 
Insurance   1,590    238,365    348,167 
Investor relations conferences and services   70,576    66,305    49,715 
Consulting   -    12,305    39,440 
Administrative services and other   16,761    62,645    1,125 
    88,927    379,620    1,002,215 

 

7.Contract payments

 

During the year ended December 31, 2020, the Company entered into an agreement with Prevail InfoWorks Inc. As part of the agreement, the Company paid $1,200,000 through the issuance of units in the private placement that closed February 28, 2020, to be applied to future regulatory and clinical trial programs. The 108,590 units issued were measured by reference to their fair value on the issuance date, which is equal to CAD $14.76 per unit.

 

 10 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

8.Intangible assets

 

Cost  Total 
   $ 
Balance, December 31, 2021   287,905 
Additions   26,005 
Foreign currency translation adjustment   (19,159)
Balance, December 31, 2022   294,751 
Additions   32,258 
Balance, September 30, 2023   327,009 

 

Accumulated amortization  Total 
    $ 
Balance, December 31, 2021   85,780 
Amortization   17,077 
Foreign currency translation adjustment   (7,940)
Balance, December 31, 2022   94,917 
Amortization   60,571 
Balance, September 30, 2023   155,488 

 

Carrying values  Total 
    $ 
At January 1, 2022   202,125 
At December 31, 2022   199,834 
At September 30, 2023   171,521 

 

The Company has licensed intellectual property from various third parties. The intangible assets relate solely to licensed intellectual property and there are no other classes of intangible assets. The intangible assets are as described below:

 

a)The Company has licensed from a third party (the “Licensor”), under patent rights purchase agreement dated July 9, 2013 and amended April 15, 2014, certain patents relating to allopurinol for the treatment of hypertension. The Company paid a total of $40,000 to the Licensor per the terms of the agreement.

 

The Company will also pay the Licensor royalties on the cumulative net revenues from the sale or sublicense of the product covered under the patent license until the later of (i) the expiration of the last patent right covering the product; and (ii) the expiration of ten years from the date of the first commercial sales of a product. As of September 30, 2023, no royalties have been paid.

 

b)In December 2012, the Company entered into an agreement to license certain intellectual property relating to the use of all uric acid lowering agents to improve the treatment of metabolic syndrome. Under this patent rights purchase agreement, between the Company and Dr. Richard Johnson and Dr. Takahiko Nakagawa (the “Vendors”), the Company will pay the Vendors a royalty based on the cumulative net revenues from the sale or sublicense of the product covered under the licensed intellectual property until the later of (i) the expiration of the last patent right covering the product; and (ii) the expiration of 10 years from the date of the first commercial sales of a product.

 

 11 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

8.Intangible assets (continued)

 

c)Pursuant to a license agreement dated October 9, 2012, as amended on June 23, 2014, between the Company and the University of Florida Research Foundation, Inc. (“UFRF”), the Company acquired the exclusive license to a patent that claims the use of any uric acid lowering agent to treat insulin resistance. The Company has paid or is obligated to pay UFRF the following:

 

i)An annual license fee of $1,000;
ii)Reimburse UFRF for United States and/or foreign costs associated with the maintenance of the licensed patents;
iii)The issuance to UFRF of 180,397 shares of common stock of the Company (160,783 have been issued to UFRF as at September 30, 2023 and December 31, 2022. Remaining shares to be issued are included in obligation to issue shares ($24,746));
iv)Milestone payments of $500,000 upon receipt of FDA approval to market licensed product in the United States of America and $100,000 upon receipt of regulatory approval to market each licensed product in each of other jurisdictions;
v)Royalty payments of up to 1.5% of net sales of products covered by the license until the later of (i) the expiration of any patent claims; or (ii) 10 years from the date of the first commercial sale of any covered product in each country. Following commencement of commercial sales, the Company will be subject to certain annual minimum royalty payments that will increase annually to a maximum of $100,000 per year. As at September 30, 2023, no royalties have been paid; and
vi)UFRF is entitled to receive a royalty of 5% of amounts received from any sub-licensee that are not based directly on product sales, excluding payments received for research and development or purchases of the Company’s securities at not less than fair market value.

 

UFRF may terminate the agreement if the Company fails to meet the above specified milestones.

 

9.Property and equipment

 

Cost  Right-of-
use asset
   Equipment   Total 
    $    $    $ 
Balance, December 31, 2021   -    -    - 
Additions   114,588    19,696    134,284 
Foreign currency translation adjustment   -    (663)   (663)
Balance, December 31, 2022   114,588    19,033    133,621 
Additions   -    4,310    4,310 
Balance, September 30, 2023   114,588    23,343    137,931 

 

Accumulated amortization 

Right-of-

use asset

   Equipment   Total 
    $    $    $ 
Balance, December 31, 2021   -    -    - 
Amortization   38,195    2,874    41,069 
Foreign currency translation adjustment   -    (126)   (126)
Balance, December 31, 2022   38,195    2,748    40,943 
Amortization   49,110    5,653    54,763 
Balance, September 30, 2023   87,305    8,401    95,706 

 

Carrying values 

Right-of-

use asset

   Equipment   Total 
    $    $    $ 
At December 31, 2022   76,393    16,285    92,678 
At September 30, 2023   27,283    14,942    42,225 

 

 12 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

9.Property and equipment (continued)

 

The Company entered into an office lease during the year ended December 31, 2022 for which a right-of-use asset was recognized (Note 11).

 

10.Accounts payable and accrued liabilities

 

  

September 30,

2023

  

December 31

2022

  

January 1

2022

 
    $    $    $ 
Trade payables   394,032    1,293,807    323,961 
Accrued liabilities   131,213    151,406    228,987 
Total   525,245    1,445,213    552,948 

 

11.Lease obligation

 

The Company has entered into an office lease expiring in 2024, with an imputed interest rate of 8% per annum. A reconciliation of the outstanding lease obligation as at September 30, 2023 is as follows:

 

   $ 
Balance, December 31, 2021  - 
Additions   114,588 
Lease payments   (36,989)
Balance, December 31, 2022   77,599 
Lease payments   (49,087)
Balance, September 30, 2023   28,512 

 

The following is a schedule of the Company’s future minimum lease payments related to the office lease obligation:

 

   September 30, 2023   December 31, 2022 
     $     $ 
2023   17,442    69,769 
2024   11,628    11,628 
Total minimum lease payments   29,070    81,397 
Less: imputed interest   (558)   (3,798)
Total present value of minimum lease payments   28,512    77,599 
Less: current portion   (28,512)   (66,090)
Non-current portion   -    (11,509)

 

12.Share capital and reserves

 

a)Authorized and issued

 

Unlimited common shares – 1,998,848 issued at September 30, 2023 (December 31, 2022 – 1,670,071).

 

The shares outstanding presented have been adjusted to reflect the effect of the 9:1 share consolidation that took place on November 10, 2023. Common shares, options and warrants and per share amounts have been adjusted for the 9:1 share consolidation unless otherwise noted.

 

 

 

 

 13 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

12.Share capital and reserves (continued)

 

b)Issuances

 

Nine months ended September 30, 2023:

 

On January 19, 2023, the Company issued 328,777 common shares for the exercise of Pre-Funded Warrants at $0.0009 per share in the amount of $296. An amount of $531,885 was transferred from reserves to share capital as a result.

 

Year ended December 31, 2022:

 

On October 7, 2022, the Company closed a public offering of: (i) 155,555 common share units ("Common Share Units") at a price of $9.00 per Common Share Unit, with each Common Share Unit consisting of one common share and one warrant ("Warrant") to purchase one common share; and (ii) 400,000 pre-funded warrant units (“Pre-Funded Units”) at a price of $8.9991 per Pre-Funded Unit, with each Pre-Funded Unit consisting of one pre-funded warrant (“Pre-Funded Warrant”) to purchase one common share and one Warrant to purchase one common share. Aggregate gross proceeds amounted to $4,999,640. The Pre-Funded Warrants have an exercise price of $0.0009 per share, and will terminate once exercised in full. The Warrants are exercisable at an exercise price of $10.98 per share expiring five years from the date of issuance.

 

The proceeds were allocated $3,714,757 to the derivative warrant liability (Note 12(g)) and the residual amounts of $359,868 and $925,015 were allocated to common shares and pre-funded warrants respectively.

 

In connection with the public offering, the Company incurred issuance costs of $1,067,153 and issued 27,777 underwriters warrants with a fair value of $185,738. The costs were allocated between common shares and derivative warrant liability in proportion to their initial carrying amounts with $317,301 recorded as a reduction of equity and $917,357 recorded as transaction costs on derivative warrant liability and pre-funded warrants.

 

On December 29, 2022, the Company issued 71,223 common shares for the exercise of Pre-Funded Warrants at $0.0009 per share in the amount of $64. An amount of $164,704 was transferred from reserves to share capital as a result.

 

Diluted Weighted Average Number of Shares Outstanding

 

   Three months ended   Nine months ended 
   September 30,
2023
   September 30,
2022
   September 30,
2023
   September 30,
2022
 
Basic weighted average shares outstanding   1,998,848    1,443,293    1,975,972    1,443,293 
Effect of outstanding securities   -    -    -    - 
Diluted weighted average shares outstanding   1,998,848    1,443,293    1,975,972    1,443,293 

 

During the three and nine month periods ended September 30, 2023 and 2022, the Company had a net loss, as such, the diluted loss per share calculation excludes any potential conversion of options and warrants that would decrease loss per share.

 

 

 

 

 

 

 14 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

12.Share capital and reserves (continued)

 

c)Common Share Purchase Warrants

 

A summary of the changes in warrants for the nine month period ended September 30, 2023 and the year ended December 31, 2022 is presented below:

 

   Number of
Warrants
   Weighted
Average
Exercise
price
 
         
Balance, December 31, 2021   569,655   $33.12 
Granted – October 7, 2022   555,555    10.98 
Balance, September 30, 2023 and December 31, 2022   1,125,210   $22.23 

 

At September 30, 2023, the weighted average contractual remaining life of the unexercised warrants was 3.41 years (December 31, 2022 – 4.15 years).

 

The following table summarizes information on warrants outstanding at September 30, 2023:

 

Exercise Price Number
Outstanding

 

Expiry date

Remaining
Contractual Life
CAD $42.26 198,333 February 9, 2026 2.36 years
  $42.93 270,211 October 15, 2026 3.04 years
  $10.53 101,111 October 15, 2026 3.04 years
  $10.98 555,555 October 7, 2027 4.02 years
  Total 1,125,210   3.41 years

 

d)Pre-Funded Warrants

 

A summary of the changes in Pre-Funded Warrants for the nine month period ended September 30, 2023 and the year ended December 31, 2022 is presented below:

 

   Number of
Warrants
   Weighted
Average
Exercise price
 
         
Balance, December 31, 2021   -    - 
Granted – October 7, 2022   400,000   $0.0009 
Exercised   (71,223)  $0.0009 
Balance, December 31, 2022   328,777   $0.0009 
Exercised   (328,777)  $0.0009 
Balance, September 30, 2023   -    - 

 

 

 

 

 

 

 15 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

12.Share capital and reserves (continued)

 

e)Finders’ and Underwriters Warrants

 

A summary of the changes in finders’ and underwriters warrants for the nine month period ended September 30, 2023 and the year ended December 31, 2022 is presented below:

 

   Number of
Warrants
   Weighted
Average
Exercise price
 
         
Balance, December 31, 2021   22,521   $39.60 
Granted – October 7, 2022   27,777    10.98 
Balance, September 30, 2023 and December 31, 2022   50,298   $23.85 

 

At September 30, 2023, the weighted average contractual remaining life of the unexercised finders’ and underwriters warrant was 3.50 years (December 31, 2022 - 4.25 years).

 

The following table summarizes information on finders’ and underwriters warrants outstanding at September 30, 2023:

 

Exercise Price Number
Outstanding
Expiry date Remaining
Contractual Life
CAD $42.30 6,377 February 9, 2026 2.36 years
  $42.93 16,144 October 15, 2026 3.04 years
  $10.98 27,777 October 7, 2027 4.02 years
  Total 50,298   3.50 years

 

The fair value of the underwriters warrants issued on October 7, 2022 was estimated at $185,738 on the date of grant using the Black-Scholes option pricing model with the following assumptions: expected life of 5.0 years; expected volatility of 100%; risk free rate of 3.66%; and expected dividend yield of 0%.

 

The risk-free interest rate is the yield on zero-coupon Canadian Treasury Bills of a term consistent with the assumed option life. The expected life of the option is the average expected period to exercise.

 

Volatility is based on available historical volatility of the Company’s share price, excluding specific time frames in which volatility was affected by specific transactions that are not considered to be indicative of the Company’s expected share price volatility. The Company has not declared dividends in the past.

 

 

 16 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

12.Share capital and reserves (continued)

 

f)Stock Options

 

The Company has an incentive Stock Option Plan (the “Plan”) for directors, officers, employees and consultants, under which the Company may issue stock options to purchase common shares of the Company provided that the amount of incentive stock options which may be granted and outstanding under the Plan at any time shall not exceed 10% of the then issued and outstanding common shares of the Company.

 

The fair value of stock options granted was estimated on the date of grant using the Black-Scholes model with the following data and assumptions:

 

  2022
Dividend yield Nil
Annualized volatility 100%
Risk-free interest rate 1.44%-3.32%
Expected life 5 years

 

The risk-free interest rate is the yield on zero-coupon Canadian Treasury Bills of a term consistent with the assumed option life. The expected life of the option is the average expected period to exercise.

 

Volatility is based on available historical volatility of the Company’s share price, excluding specific time frames in which volatility was affected by specific transactions that are not considered to be indicative of the Company’s expected share price volatility. The Company has not declared dividends in the past.

 

Share-based payment expense recognized during the three and nine months ended September 30, 2023 amounted to$ 21,850 and $92,169 (2022 - $19,268 and $420,258) and related to vesting of options issued in prior years.

 

 17 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

12.Share capital and reserves (continued)

 

f)Stock Options (continued)

 

A summary of the changes in stock options for the nine month period ended September 30, 2023 and the year ended December 31, 2022 is presented below:

 

   Number of
Options
   Weighted
Average
Exercise
price (CAD)
 
Balance, December 31, 2021   67,329   $27.90 
Granted – January 12, 2022   14,162    22.86 
Granted – June 6, 2022   43,866    14.40 
Granted – November 25, 2022   7,776    12,42 
Expired   (4,896)   28.71 
Balance, December 31, 2022   128,237   $27.90 
Expired   (14,566)   48.60 
Balance, September 30, 2023   113,671   $18.27 
Vested and exercisable, September 30, 2023   95,004   $18.54 

 

The weighted average contractual remaining life of the unexercised options was 3.04 years (December 31, 2022 - 3.43 years).

 

The following table summarizes information on stock options outstanding at September 30, 2023:

 

 

Exercise
Price (CAD)

Number
Outstanding

Number

Exercisable

Expiry Date Remaining
Contractual Life
$52.83 2,366(1) 2,366   November 5, 2023 0.10 years
$14.76 18,927 18,927   June 23, 2025 1.73 years
$25.38 1,419 1,419   August 27, 2025 1.91 years
$29.61 6,624 6,624   January 11, 2026 2.28 years
$16.92 2,366 2,366   May 12, 2026 2.62 years
$15.84 2,366 2,366   June 16, 2026 2.71 years
$21.69 6,353(1) 4,588   July 14, 2026 2.79 years
$22.86 9,607 9,607   December 21, 2026 3.23 years
$22.86 12,701(1) 7,058   January 12, 2027 3.29 years
$14.40 43,866 37,723   June 6, 2027 3.68 years
$12.42 7,076(1) 1,966   November 25, 2027 4.16 years
  113,671 95,014      

 (1) 6,271 options were cancelled or expired unexercised subsequent to September 30, 2023.

 

g)Derivative warrant liability

 

During the years ended December 31, 2022 and 2021, the Company issued warrants which were recorded as derivative financial liabilities as the exercise price was denominated in a currency other than the functional currency of the Company and therefore may be settled other than by the exchange of a fixed amount of cash. These warrants are revalued at each reporting period and any gain or loss is recorded in profit or loss.

 

 18 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

12.Share capital and reserves (continued)

 

g)Derivative warrant liability (continued)

 

The fair value of the warrants issued during the year ended December 31, 2022 was estimated at $3,714,757 on the date of grant using the Black-Scholes option pricing model with the following assumptions: share price on date of grant of $9.09; exercise price of the warrant of $10.98; expected life of 5.0 years; expected volatility of 100%; risk free rate of 3.66%; and expected dividend yield of 0%.

 

During the period ended September 30, 2023, with the change in functional currency of the Company to USD, the exercise price of these warrants is now denominated in the functional currency of the Company and therefore these warrants no longer meet the definition of a derivative warrant liability and instead meet the definition of equity instruments. Accordingly, all warrants recorded as derivative financial liabilities on January 1, 2023, the date of the change in functional currency, were reclassified to equity instruments at their estimated fair value as of that date.

 

The balance of the derivative warrant liabilities (level 3) is as follows:

 

     
Balance at December 31, 2021  $3,626,375 
Warrants issued October 7, 2022   3,714,757 
Fair value adjustment   (3,486,729)
Balance at December 31, 2022  $3,854,403 
Reclassified to reserves   (3,854,403)
Balance at September 30, 2023   - 

 

Significant weighted average assumptions used in determining the fair value of the derivative warrant liabilities at December 31, 2022 are as follows:

 

  

December 31,

2022

 
Share price  $7.29 
Risk-free interest rate   3.55%
Dividend yield   0%
Expected volatility   100%
Remaining term (in years)   3.8-4.8 

 

The fair value is classified as level 3 as expected volatility is determined using historical volatility and is therefore not an observable input.

 

 19 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

13.Related party transactions

 

All related party transactions were measured at the amount of consideration established and agreed to by the related parties. All amounts due from/payable to related parties are unsecured, non-interest bearing and have no fixed terms of repayment.

 

During the three and nine months ended September 30, 2023 and 2022, the Company incurred the following transactions with related parties:

 

a)Wages and benefits and professional fees were paid or accrued to Allen Davidoff, the Chief Executive Officer (“CEO”), Amar Keshri, former Chief Financial Officer (“CFO”), and David MacDonald, former Chief Technology Officer (“CTO”) in the amount of $80,250 and $324,597 (2022 - $112,595 and $404,811).

 

b)Fees were paid or accrued to 1282803 Ontario Inc., a company owned by James Fairbairn, the Chief Financial Officer (“CFO”) of the Company in the amount of $38,325 and $38,325 (2022 - $nil and $nil)

 

c)Research and development fees were paid or accrued to Haworth Biopharmaceutical, a company owned by Stephen Haworth, the Chief Medical Officer (“CMO”) of the Company in the amount of $56,250 and $165,479 (2022 - $57,164 and $169,724).

 

d)Consulting fees were paid or accrued to Stacy Evans, the Chief Business Officer (“CBO”) of the Company in the amount of $75,000 and $225,000 (2022 - $nil and $nil).

 

e)Directors’ fees were paid or accrued to the directors of the Company in the amount of $45,278 and $136,862 (2022 - $48,238 and $84,087). The amount includes director fees payment of $34,064 and $100,148 for the three and nine months ended September 30, 2023 (2022 - $35,486 and $40,682) to Anthony Giovinazzo, Chairman of the Company.

 

f)As at September 30, 2023, $8,876 (December 31, 2022 - $14,914) was payable to directors of the Company, $nil (December 31, 2022 - $28,846) was accrued to the CEO of the Company, for CEO services, $nil (December 31, 2022 - $10,904) was accrued to the former CFO of the Company, for CFO services, $14,313 (December 31, 2022 - $nil) was accrued to the CFO of the Company, for CFO services, $18,750 (December 31, 2022 - $49,998) was payable and accrued to the CMO of the Company, for consulting services, and $25,000 (December 31, 2022 - $24,999) was payable and accrued to the CBO of the Company, for consulting services. The balances are unsecured, non-interest bearing, and have no fixed terms of repayment.

 

g)Management and directors’ compensation transactions for the three and nine months ended September 30, 2023 and 2022 are summarized as follows:

 

 

   Management
Compensation
  

Directors’

fees

   Share-
based
payments
  

 

 

Total

 
    $    $    $    $ 
Three months ended September 30, 2022                    
Directors and officers   169,759    48,238    36,332    254,329 
                     
Three months ended September 30, 2023                    
Directors and officers   249,825    45,278    11,874    306,977 

 

 20 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

 

13.Related party transactions (continued)

 

   Management
Compensation
  

Directors’

fees

   Share-
based
payments
  

 

 

Total

 
    $    $    $    $ 
Nine months ended September 30, 2022                    
Directors and officers   574,732    84,087    372,331    1,031,150 
                     
Nine months ended September 30, 2023                    
Directors and officers   753,401    136,862    55,820    946,083 

 

14.Financial instruments and risk management

 

The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued liabilities, lease obligation and derivative warrant liability. Cash and cash equivalents are classified as a financial asset at FVTPL, accounts payable and accrued liabilities and lease obligation are classified as financial liabilities at amortized cost and warrant liability is classified as a financial liability at FVTPL.

 

The fair values of these financial instruments approximate their carrying values at September 30, 2023, due to their short-term nature.

 

The Company thoroughly examines the various financial instruments and risks to which it is exposed and assesses the impact and likelihood of those risks. These risks include foreign currency risk, interest rate risk, market risk, credit risk, and liquidity risk. Where material, these risks are reviewed and monitored by the Board of Directors

 

There have been no changes in any risk management policies since December 31, 2022.

 

15.Capital management

 

The Company defines capital that it manages as shareholders’ equity. The Company manages its capital structure in order to have funds available to support its research and development and sustain the future development of the business. When managing capital, the Company’s objective is to ensure the entity continues as a going concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders. Management adjusts the capital structure as necessary in order to support its activities.

 

Since inception, the Company’s objective in managing capital is to ensure sufficient liquidity to finance its research and development activities, general and administrative expenses, expenses associated with intellectual property protection and its overall capital expenditures. There were no changes during the nine months ended September 30, 2023. The Company is not exposed to external requirements by regulatory agencies regarding its capital.

 

 21 

XORTX THERAPEUTICS INC.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2023 and 2022

(Unaudited - expressed in U.S. Dollars)

16.Commitments

 

The Company has long-term arrangements with commitments that are not recognized as liabilities as at September 30, 2023 and December 31, 2022 are as follows:

 

a)Employment Agreements

 

  

September 30,

2023

  

December 31,

2022

 
    $    $ 
Management services – officers   321,000    441,7541 

1 The former CFO of the Company had a termination clause whereby he was entitled to the equivalent of 12 times his then current monthly salary which as of December 31, 2022, equated to an annual salary of CAD $192,000.

 

The President, CEO and a director of the Company has a long-term employment agreement with the Company. The agreement has a termination clause whereby he is entitled to the equivalent of 12 times his then current monthly salary which, as of September 30, 2023 and December 31, 2022, equated to an annual salary of $321,000 and $300,000.

 

b)Payments

 

In the normal course of business, the Company has committed to payments totaling $310,000 (December 31, 2022 - $1,994,232) for activities related to its clinical trial, manufacturing, collaboration programs and other regular business activities which are expected to occur over the next two years.

 

17.Segmented information

 

The Company operates in one reportable operating segment, being the development and commercialization of therapies to treat progressive kidney disease. As the operations comprise a single reporting segment, amounts disclosed also represent segment amounts. All long-term assets of the Company are located in Canada.

 

18.Events after the reporting period

 

On October 27, 2023, the shareholders of the Company approved a consolidation of the common shares on a basis of 1 post-Consolidation common shares for 9 pre-consolidation common shares (the “Consolidation”). The share consolidation was completed on November 10, 2023.

 

22